Cost-effectiveness of Neoadjuvant Pembrolizumab in Head and Neck Cancer Demonstrated
The KEYNOTE-689 trial showed that neoadjuvant pembrolizumab followed by adjuvant therapy significantly improved event-free survival compared to standard of care.
Phase III
Oncology / Head and Neck Squamous Cell Carcinoma
Status
Positive
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The cost-effectiveness of neoadjuvant pembrolizumab positions it as a potentially preferred treatment option in the competitive landscape of head and neck cancer therapies. This could significantly influence pricing and reimbursement strategies, impacting market share against existing therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor further data releases from the KEYNOTE-689 trial and any subsequent changes in treatment guidelines for LA HNSCC.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.